Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy

In 2018, a multi‐disciplinary workshop was held at the Massachusetts General Hospital to discuss challenges in defining, diagnosing, and treating immune‐related adverse events (irAE), including those that occur in patients administered PD‐1/L1 inhibitor combination therapy. In this commentary, the w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zubiri, Leyre, Allen, Ian M., Taylor, Martin S., Guidon, Amanda C., Chen, Steven T., Schoenfeld, Sara R., Neilan, Tomas G., Sise, Meghan E., Mooradian, Meghan J., Rubin, Krista M., Leaf, Rebecca Karp, Parikh, Aparna R., Faje, Alexander, Gainor, Justin F., Cohen, Justine V., Fintelmann, Florian J., Kohler, Minna J., Dougan, Michael, Reynolds, Kerry L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066708/
https://www.ncbi.nlm.nih.gov/pubmed/32162817
http://dx.doi.org/10.1634/theoncologist.2018-0883

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066708/
https://www.ncbi.nlm.nih.gov/pubmed/32162817
http://dx.doi.org/10.1634/theoncologist.2018-0883

Ejemplares similares